Nature Communications · 2020 · 1.1K citations · 36 references
Life SciencesImmunologyInfectious DiseasesHost-pathogen InteractionsInnate ImmunityVirologyAntiviral ImmunityInnate Immune ActivationInnate Immune ResponseInterferon ResponsesViral InfectionsViral PathogenesisAntiviral Innate SignalingDownstream Immune SignalingInhibition Of Interferon ResponsesInnate Immunity PathwaysInterferon Response To Viral InfectionSars-cov-2 InfectionType I Interferon InductionType I Interferon Responses
The pandemic of COVID-19 has posed an unprecedented threat to global public health. However, the interplay between the viral pathogen of COVID-19, SARS-CoV-2, and host innate immunity is poorly understood. Here we show that SARS-CoV-2 induces overt but delayed type-I interferon (IFN) responses. By screening 23 viral proteins, we find that SARS-CoV-2 NSP1, NSP3, NSP12, NSP13, NSP14, ORF3, ORF6 and M protein inhibit Sendai virus-induced IFN-β promoter activation, whereas NSP2 and S protein exert opposite effects. Further analyses suggest that ORF6 inhibits both type I IFN production and downstream signaling, and that the C-terminus region of ORF6 is critical for its antagonistic effect. Finally, we find that IFN-β treatment effectively blocks SARS-CoV-2 replication. In summary, our study shows that SARS-CoV-2 perturbs host innate immune response via both its structural and nonstructural proteins, and thus provides insights into the pathogenesis of SARS-CoV-2.
36
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Lena Alexopoulou, Agnieszka Czopik Holt, Ruslan Medzhitov et al. · Nature · 2001 · 6.1K citations